We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+24.55%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
AUM
$8.79B
AUM Growth
+$1.45B
Cap. Flow
-$72.5M
Cap. Flow %
-0.82%
Top 10 Hldgs %
20.48%
Holding
2,420
New
180
Increased
1,163
Reduced
213
Closed
125

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$8.64M
2
WORK
Slack Technologies, Inc.
WORK
+$7.6M
3
ABBV icon
AbbVie
ABBV
+$7.02M
4
TMUS icon
T-Mobile US
TMUS
+$6.46M
5
OTIS icon
Otis Worldwide
OTIS
+$5.52M

Sector Composition

Rank Sector Weight
1 Technology 21.58%
2 Healthcare 14.02%
3 Financials 12.88%
4 Consumer Discretionary 10.4%
5 Industrials 9.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CETV
2051
DELISTED
Central European Media Enterprises Ltd
CETV
$153K ﹤0.01%
43,273
OOMA icon
2052
Ooma
OOMA
$553M
$153K ﹤0.01%
9,258
HAFC icon
2053
Hanmi Financial
HAFC
$956M
$152K ﹤0.01%
15,681
BZH icon
2054
Beazer Homes USA
BZH
$874M
$152K ﹤0.01%
+15,116
New +$121K
FORR icon
2055
Forrester Research
FORR
$220M
$152K ﹤0.01%
4,738
HOME
2056
DELISTED
At Home Group Inc.
HOME
$152K ﹤0.01%
+23,363
New +$95.6K
ALRS icon
2057
Alerus Financial
ALRS
$843M
$151K ﹤0.01%
+7,649
New +$138K
HCKT icon
2058
Hackett Group
HCKT
$278M
$151K ﹤0.01%
11,151
MSBI icon
2059
Midland States Bancorp
MSBI
$696M
$150K ﹤0.01%
10,034
LAND
2060
Gladstone Land Corp
LAND
$353M
$149K ﹤0.01%
9,389
CTSO icon
2061
Cytosorbents Corp
CTSO
$23.3M
$148K ﹤0.01%
+14,976
New +$138K
RIGL icon
2062
Rigel Pharmaceuticals
RIGL
$782M
$148K ﹤0.01%
8,099
+4,124
+104% +$74.2K
PAYS icon
2063
Paysign
PAYS
$723M
$148K ﹤0.01%
+15,230
New +$112K
BCLI
2064
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$148K ﹤0.01%
+877
New +$94.6K
PARR icon
2065
Par Pacific Holdings
PARR
$3.9B
$146K ﹤0.01%
16,282
BY icon
2066
Byline Bancorp
BY
$1.78B
$146K ﹤0.01%
11,156
OFLX icon
2067
Omega Flex
OFLX
$304M
$146K ﹤0.01%
1,378
DGII icon
2068
Digi International
DGII
$3.23B
$146K ﹤0.01%
12,500
CALA
2069
DELISTED
Calithera Biosciences, Inc
CALA
$145K ﹤0.01%
1,375
ROAD icon
2070
Construction Partners
ROAD
$6.9B
$145K ﹤0.01%
8,165
RGP icon
2071
Resources Connection
RGP
$144M
$145K ﹤0.01%
12,083
AMRS
2072
DELISTED
Amyris Inc.
AMRS
$144K ﹤0.01%
+33,752
New +$112K
ETD icon
2073
Ethan Allen Interiors
ETD
$575M
$144K ﹤0.01%
12,159
PBYI icon
2074
Puma Biotechnology
PBYI
$459M
$144K ﹤0.01%
13,791
LAB icon
2075
Standard BioTools
LAB
$312M
$144K ﹤0.01%
+35,855
New +$125K

Similar funds

MetLife Investment Management's Q2 2020 Portfolio in Review

As of Q2 2020, MetLife Investment Management held 2,420 positions worth $8.79B, up 20% from $7.34B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

MetLife Investment Management's Q2 2020 filing shows 180 new, 1,163 increased, 213 reduced and 125 closed positions. Its largest new stake was DexCom: 96,564 shares worth $9.79M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $143M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • MetLife Investment Management's largest Q2 2020 buy was DexCom: 96,564 shares worth $9.79M.
  • MetLife Investment Management added most to AbbVie in Q2 2020, an estimated $7.02M increase.
  • MetLife Investment Management's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $143M.
  • MetLife Investment Management fully exited Allergan plc in Q2 2020, selling an estimated $15M.
  • MetLife Investment Management's ten largest holdings make up 20% of its $8.79B portfolio in Q2 2020.
  • MetLife Investment Management opened 180 new positions and closed 125 in Q2 2020.
  • MetLife Investment Management's portfolio value rose 20% quarter-over-quarter to $8.79B.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.